Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis-Reference-Cited by-同舟云学术

Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis

Published:2013-11 Issue:1 Volume:43 Page:49-53
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

van der Heijde D,Zack D,Wajdula J,Sridharan S,Koenig AS

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/03009742.2013.834961

Reference18 articles.

1. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept

2. Bacterial and opportunistic infections during anti-TNF therapy

3. Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies

4. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study;Modern Rheumatology;2024-01-31

2. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension;RMD Open;2022-07

3. Risk of cancer in patients with ankylosing spondylitis: a nationwide cohort study in Taiwan;Scandinavian Journal of Rheumatology;2021-01-19

4. Risk of Malignancy in Spondyloarthritis;Rheumatic Disease Clinics of North America;2020-08

5. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies;Clinical Microbiology Reviews;2020-06-17